Skip to content

Luteal Phase Support in MOH/IUI treatment (LUMO study)

Luteal Phase Support in MOH/IUI treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON24508
Enrollment
1008
Registered
2021-08-10
Start date
2022-12-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unexplained Infertility/ sub fertility

Interventions

Exogenous progesterone (Utrogestan)

Sponsors

ZonMW
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Couples starting IUI with Mild Ovarian HyperStimulation (MOH), with the intend to receive this treatment for at least six months. - Diagnosis of unexplained (primary or secondary) infertility - Hunault 30%, after an expectant management period of at least 6 additional months). - Females aged >18 years with regular menstrual cycle. - Total mobile sperm count (VCM) >10 million.

Exclusion criteria

Exclusion criteria: - Uterine anomalies - Endometriosis gr 3-4 - Endocrine anomalies

Design outcomes

Primary

MeasureTime frame
Pregnancy within 6 months of treatment, leading to Live birth.

Secondary

MeasureTime frame
Clinical pregnancy rate (Number and rate op patients that achieve a clinical pregnancy within 6 months). Miscarriage rate (Number and rate of patients that experience a miscarriage (16 weeks gestation), gestational diabetes, preeclampsia, HELLP syndrome or pregnancy induced hypertension, within one year). Perinatal outcomes (stillbirth, live birth, perinatal death <6 weeks, gestational age and birthweight). Side effects (e.g. nausea, stomach ache, vaginal discharge, other (self reported) side effects) within treatment cycle) and compliance to therapy (use of medication as prescribed during treatment cycles). Added Medication Costs (increase in total therapy costs due to the addition of utrogestan). Budget impact (economic assessment that estimates financial consequences of adopting a new intervention).

Contacts

Public ContactKatja Drechsel

UMC Utrecht

k.c.e.drechsel-2@umcutrecht.nl+31624343118

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)